Intuitive Surgical (ISRG) Stock May Be Fairly Valued On New Robotics Competition
π Intuitive Surgical stock has gained 56.5% over the past three years, trading at US$427.86.
β οΈ Johnson & Johnson's FDA-cleared OTTAVA system introduces new competition that may affect Intuitive Surgical's future procedure volumes and pricing power.
π° The company generated approximately $2.7 billion in free cash flow over the latest twelve months.
π DCF projections assume Intuitive Surgical's free cash flow will reach roughly $5.9 billion by 2030.
π Bull case scenarios suggest Intuitive Surgical is 20% undervalued due to its robust recurring revenue model and strong moat.
π» Bear case scenarios indicate the stock may be 32% overvalued as current prices reflect strong growth and high margins.
Bullish Signals
- Intuitive Surgical has generated approximately $2.7 billion in free cash flow over the latest twelve months, demonstrating strong cash generation capabilities.
- The company possesses a robust business model characterized by recurring revenue from instrument purchases, maintenance services, and software updates.
Risk Factors
- Johnson & Johnson's FDA-cleared OTTAVA system introduces new competition that could negatively impact Intuitive Surgical's future procedure volumes and pricing power.
Full Analysis
Intuitive Surgical (ISRG) stock is currently trading at US$427.86, reflecting a 56.5% gain over the past three years. The article evaluates whether this valuation remains justified given new competition in the robotic surgery sector, specifically Johnson & Johnson's FDA-cleared OTTAVA system, which could impact Intuitive Surgical's future procedure volumes and pricing power.
A Discounted Cash Flow (DCF) analysis suggests that Intuitive Surgical's current share price is broadly aligned with its intrinsic value. The model projects free cash flow rising from approximately $2.7 billion in the latest twelve months to around $5.9 billion by 2030, assuming growth rates gradually slow as the business matures.
Market sentiment regarding Intuitive Surgical is divided between a bullish view that the company's recurring revenue model and strong moat make it 20% undervalued, and a bearish view that current numbers imply the stock is already fully priced in, potentially making it 32% overvalued with limited room for disappointment.